How we indicate oral antidiabetics today (from metformin to gliptins and gliflozins)

Czech version

Authors: Štěpán Svačina
Authors‘ workplace: III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2014; 60(9): 777-781
Category:

Overview

Today we treat Type 2 diabetes mellitus by gradually adding antidiabetics from monotherapy to double, triple and multi combinations of medicines. Metformin still remains the first-line medicine, if well tolerated and not contraindicated. In the next step, we have a wide choice of 5 groups of medicines at least. The new algorithms used in the U.S.A. introduce some degree of preference for the incretin therapy (gliptins and incretin analogues) and the new groups of gliflozins over the standard treatments. In the near future, the indication of antidiabetics is therefore about to undergo big changes or at least a discussion about the preferences of the individual groups of medicines including those new to diabetology.

Key words:
gliflozins –⁠ gliptins –⁠ incretin therapy –⁠ metformin –⁠ oral antidiabetics –⁠ type 2 diabetes mellitus

Sources

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55(6): 1577–1596.

2. Svačina Š. Přístup zaměřený na pacienta –⁠ cesta k opravdové individualizaci léčby diabetu. Medicína po promoci 2012; 13(4): 49–52.

3. Karen I et al. Doporučený postup péče o pacienty s diabetes mellitus. Praha: Společnost všeobecného lékařství ČLS 2013. Dostupné z WWW: <http://www.svl.cz>.

4. Garber AJ, Abrahamson MJ, Barzilay JI et al. American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013. Consensus Statement. Endocr Pract 2013; 19(Suppl 2): 1–48.

5. Garber AJ, Abrahamson MJ, Barzilay JI et al. American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013. Endocr Pract 2013; 19(2): 327–336.

6. Svačina Š. Systémové účinky metforminu. Postgrad med 2010; 12(Suppl Interna): 42–45.

7. Šmahelová A. Pioglitazon –⁠ využití v léčbě diabetika 2. typu. Kap Kardiol 2013; 5(4): 122–125.

8. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Mladá Fronta: Praha 2010. ISBN: 9788020422477.

9. Rudolfsky G, Rüssmann HJ, Siegmund T. Inhibice kotransportérů SGLT2: účinný způsob léčby diabetu? Medicína po promoci 2014; 15(1): 8–14.

10. Ferrannini E et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124(2): 499–508.